Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCMA-CD19 cCAR T cells · 1 trial · 1 indication
Evaluation all possible adverse reactions, including the number, incidence, and severity of symptoms such as cytokine release syndromes and neurotoxicity within 3 months after BCMA-CD19 cCAR infusion.
| Arm | Type | Description |
|---|---|---|
| BCMA-CD19 cCAR T cells | EXPERIMENTAL | Dose escalation phase: patient's T cells will be transduced with a retroviral vector to express a BCMA-CD19 cCAR. with an escalation approach. |
| Name | Type | Description |
|---|---|---|
| BCMA-CD19 cCAR T cells | BIOLOGICAL | • BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy. |
Inclusion Criteria: * 1\. Age: 18\~60 years old; 2. Diagnosed with immune thrombocytopenia associated with autoimmune diseases including systemic lupus erythematosus (according to the 1997 or 2009 ACR classification criteria), primary Sjogren's syndrome (according to the 2002 ACR/EULAR internationa...
BCMA-CD19 cCAR T cells is an investigational cell therapy being studied for refractory immune cytopenia, a condition involving low blood cell counts associated with autoimmune diseases. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BCMA-CD19 cCAR T cells is designed to target BCMA and CD19, two proteins found on certain immune cells. By engineering T cells to recognize these targets, the therapy aims to address the underlying autoimmune response in refractory immune cytopenia.
BCMA-CD19 cCAR T cells is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The therapy is currently in Phase 1 clinical trials for refractory immune cytopenia.
BCMA-CD19 cCAR T cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not yet been approved by the FDA or other regulatory agencies. The ongoing trial is recruiting participants to evaluate its safety and efficacy.
BCMA-CD19 cCAR T cells is being studied in a Phase 1 clinical trial registered as NCT06787989, titled 'BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases.' The trial is recruiting 20 participants in China and is not randomized or blinded.